OXFENDAZOLE

/static/temp/default.svg

Search structure


Synonyms	NSC-758943 Oxfendazole RS-8858 Synanthic
Status
Molecule Category	UNKNOWN
UNII	OMP2H17F9E
EPA CompTox	DTXSID9044112


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BEZZFPOZAYTVHN-UHFFFAOYSA-N
Smiles	COC(=O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1
InChI	InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H13N3O3S
Molecular Weight	315.35
AlogP	2.91
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	84.08
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	22.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM	Homo sapiens	0.0 %
Inhibition of human FAAH at 1 uM	Homo sapiens	16.49 %
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)	None	844.0 nM
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control	Mus musculus	55.0 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	95.15 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	114.17 %
PubChem BioAssay. nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50. (Class of assay: confirmatory)	None	468.3 nM
PubChem BioAssay. Increased HeLa cells with 2N DNA content-IC50. (Class of assay: confirmatory)	None	326.3 nM
PubChem BioAssay. RKO viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)	None	1.0 nM
PubChem BioAssay. Decreased HeLa cell count-IC50. (Class of assay: confirmatory)	None	257.5 nM
PubChem BioAssay. HCT116 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)	None	1.0 nM
PubChem BioAssay. VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50. (Class of assay: confirmatory)	None	288.4 nM
PubChem BioAssay. Increased HeLa cells with 4N DNA content-IC50. (Class of assay: confirmatory)	None	331.0 nM
PubChem BioAssay. alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50. (Class of assay: confirmatory)	None	559.3 nM
PubChem BioAssay. GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)	None	1.0 nM
PubChem BioAssay. Increased chromatin condensation in HeLa cells-IC50. (Class of assay: confirmatory)	None	241.1 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	6.44 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	-0.6992 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.03 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.03 %

Cross References

Resources	Reference
ChEBI	35812
ChEMBL	CHEMBL42442
DrugBank	DB11446
FDA SRS	OMP2H17F9E
Human Metabolome Database	HMDB0031812
PubChem	40854
SureChEMBL	SCHEMBL44121

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).